Ultragenyx Pharmaceutical Inc. (RARE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ultragenyx Pharmaceutical Inc. (RARE) is up 26.2% since the beginning of the year. At $29 per share, RARE is trading 31.5% below its 52-week high of $42. Investors who bought $1,000 worth of RARE shares 5 years ago would now be looking at an investment worth $310.

Ultragenyx Pharmaceutical Inc. (RARE) has returned 26.22% so far this year and -21.84% over the past 12 months. Over the last ten years, RARE has returned -5.13% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jan 31, 2014, RARE's average daily return is +0.05%, while the average monthly return is +0.99%. At this rate, an investment would double in approximately 5.9 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2015 with a return of +54.2%, while the worst month was Jan 2016 at -50.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RARE closed higher 50% of trading days. The best single day was Jan 10, 2020 with a return of +23.4%, while the worst single day was Dec 29, 2025 at -42.3%.

Ultragenyx Pharmaceutical Inc. has an annualized alpha of -3.36%, beta of 1.31, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since January 31, 2014.

• This stock participated in 125.84% of S&P 500 Index downside but only 56.23% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RARE ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ultragenyx Pharmaceutical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ultragenyx Pharmaceutical Inc. was 89.57%, occurring on Mar 24, 2026. The portfolio has not yet recovered.

The current Ultragenyx Pharmaceutical Inc. drawdown is 83.63%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ultragenyx Pharmaceutical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ultragenyx Pharmaceutical Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.